Syed Yahiya Y
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2021 Jan;81(1):157-168. doi: 10.1007/s40265-020-01437-2.
Alemtuzumab (Lemtrada) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse rates (in treatment-naïve or -experienced patients) and disability progression (treatment-experienced patients). Treatment benefits were maintained over up to 9 years of follow-up, with ≈ 50% of patients not requiring retreatment. The efficacy of alemtuzumab in patients with highly active disease was generally similar to that in the overall population. Alemtuzumab has an acceptable tolerability profile, with infusion-associated reactions, infections and autoimmunity being the main safety and tolerability issues. Current evidence indicates that alemtuzumab is an effective treatment option for adults with highly active RRMS, with an acceptable safety and tolerability profile and convenient treatment regimen.
阿仑单抗（利卓普明）是一种抗CD52单克隆抗体，在欧盟被批准用于治疗高度活动性复发缓解型多发性硬化症（RRMS）。在活动性RRMS患者的3期试验中，静脉注射阿仑单抗在降低复发率（初治或经治患者）和残疾进展（经治患者）方面比皮下注射干扰素β-1a更有效。治疗益处维持了长达9年的随访，约50%的患者无需再次治疗。阿仑单抗在高度活动性疾病患者中的疗效与总体人群大致相似。阿仑单抗具有可接受的耐受性，输液相关反应、感染和自身免疫是主要的安全性和耐受性问题。目前的证据表明，阿仑单抗是治疗高度活动性RRMS成人患者的有效选择，具有可接受的安全性和耐受性以及方便的治疗方案。
